INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-SCT) can be a curative treatment for pediatric patients with hematologic malignancies, bone marrow failure syndromes and some inherited disorders. 1, 2 The main obstacles for a successful allo-SCT are relapse of the underlying disease, GvHD and infection. [3] [4] [5] [6] Over the past decades, the practice of allo-SCT has considerably evolved. [7] [8] [9] [10] [11] [12] [13] New sources of hematopoietic stem cells, such as peripheral blood stem cells and umbilical cord blood (UCB), 14, 15 have become available. The advent of reduced intensity conditioning (RIC) regimens has provided a curative option to patients who otherwise would not have undergone allo-SCT. [16] [17] [18] Moreover, mycophenolate mofetil has been introduced for GvHD prophylaxis, [19] [20] [21] [22] higher resolution and number of loci can now be tested for HLA matching, 23 development of antifungal therapy and long-term follow-up has benefited from improved management. 24 However, the long-term outcome studies have mainly involved adult patients. 25, 26 To determine whether these advantages equally applied to the outcome of allo-SCT in children and adolescents, we conducted a retrospective study on pediatric patients who underwent allo-SCT in our center during the last three decades.
PATIENTS AND METHODS Patients
All patients who received allo-SCT in the Department of Pediatric Hematology, Nantes Hospital (France), were evaluated between the year of the first allo-SCT in our department, 1983, and 2010. This period was a priori divided into two, namely 1983-1999 and 2000-2010 , the latter corresponding to the initiation and development of UCB allo-SCT and RIC regimen in our Institution. The standard risk (SR) group was composed of AML in first CR1, ALL in CR1 and CR2, aplastic anemia and hematological non-malignancies. [27] [28] [29] The high-risk (HR) group was defined by AML4CR1, ALL4CR2, lymphomas and all malignant diseases in PR, progressive evolution or relapse. As part of current practice, patients and donors gave their approval for use of their data for research purposes. The study was approved by the local Institutional review board.
All patients received a preparative regimen followed by the infusion of donor cells as in patients in private rooms, and they remained hospitalized until hematopoietic and clinical recovery. TBI in combination with cyclophosphamide (Cy) and/or VP16 was commonly used in children undergoing allo-SCT for ALL. High-dose busulfan combined with cyclophosphamide and TBI-cyclophosphamide were the two most commonly used myeloablative conditioning regimens for AML. The regimen was considered of 'reduced intensity' if the dose of busulfan was ⩽ 8 mg/kg orally or o6.4 mg/kg intravenously, melphalan was o150 mg/m 2 , and the TBI dose was 200 or 400 cGy. 30 GvHD prophylaxis was based on cyclosporine except for patients who received a syngeneic transplant. Cyclosporine was administered alone or in association with methotrexate, mycophenolate mofetil or methylprednisone.
During the whole-study period, all blood products were filtered, irradiated and screened for CMV. Prophylaxis against infections included low-dose acyclovir, trimethoprim-sulfamethazole, an antifungal agent (usually fluconazole) and oracillin or amoxicillin. In patients with neutropenia, empiric broad-spectrum antibiotics were started for a body temperature 438.3°C and/or clinical signs of infection. After 2000, antifungal treatment opportunities were extended as new agents became available computed tomography scans have been realised systematically to look for fungal infection at the pre-transplant assessment since 2000. Under suspicion of fungal infections, computed tomography scans were performed consistently since 2000-2001. In the first 100 days post allo-SCT, after 2000, patients were assessed at least once per week for CMV and EBV reactivation by a PCR assay to initiate pre-emptive ganciclovir. In the latest years, EBV reactivation was treated with rituximab infusions. 31 After 2000 viral screening was extended to adenovirus and HHV6 and cidofovir became available for treatment. IV Igs were infused in case of infectious disease associated with hypogammaglobulinemia or in case of viral infections or reactivation. This practice was similar over the two periods. Concerning anti-pneumoccal vaccination, conjugate vaccines were routinely used until the marketing authorization of polysaccharide vaccine in 2002. Enteral nutrition support managed by a pediatric gastroenterologist was systematically introduced during the past decade.
Outcome measurements
These include overall survival (OS), PFS, non-relapse mortality (NRM) and relapse incidence. The data were locked on 1 January 2013. For NRM, we considered all deaths occurring after allo-SCT that were not caused by relapse or progression of the underlying disease. The severity of acute GvHD was graded according to the Glucksberg classification. 32 The severity of chronic GvHD was graded as limited or extensive, according to the historical classification. 33 Because of the retrospective nature of the study and its spread over time, the National Institutes of Health revised criteria could not be applied. 34 
Statistical analysis
The probabilities of OS, PFS, relapse incidence and NRM were the primary study end points. Patient-and transplant-related variables were compared between periods using the χ 2 statistic for categorical and the MannWhitney test for continuous variables. PFS and OS were calculated among patients using the Kaplan-Meier estimate. NRM was evaluated using the cumulative incidence (CI) method with relapse as a competing event. 22 Acute or chronic GvHD were calculated among allografts using CI in a competing risk setting, with death in remission treated as a competing event. 35 For univariate analyses, continuous variables were categorized and the median was used as a cutoff point. Univariate analyses were performed with the use of log-rank test for OS and LFS, whereas the Gray test was applied for relapse incidence and NRM. The type I error rate was fixed at 0.05 for determination of factors associated with time to event Abbreviations: ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; BM = bone marrow; CML = chronic myeloid leukemia; CMML = chronic myelomonocytic leukemia; JMML = juvenile myelomonocytic leukemia; MDS = myelodysplasia syndrome; MISRD = mismatched related donor; MISUD = mismatched unrelated donor; MPS = myeloproliferative syndrome; MRD = matched related donor; MUD = matched unrelated donor; NHL = non-Hodgkin leukemia; PBSC = peripheral blood stem cell; UCB = unrelated cord blood. High risk: progressive/refractory disease or relapse. a standard risk: hemoglobinopathy and disease in CR (CR1, CR2, CR3). 
RESULTS

Characteristics of the patients
In total, 250 patients were allografted and 272 allo-SCT procedures were performed. The main characteristics of the patients and the most relevant aspects of allo-SCT are shown in Table 1 ). After 2000, UBC was used as the SC graft for 26% allo-SCT procedures and peripheral blood stem cells for 9%. Between 1983 and 1999, 70% of allo-SCT were HLA-identical siblings versus 37% after 2000 (P = 3.10 − 9 ). The risk status was comparable between the two groups (P = 0.52).
Outcome measurements
The 5-year OS of the whole cohort was 59% (CI: 53-66). OS was significantly lower in the 1983-1999 period compared with the 2000-2010 period (52% versus 64%, P = 0.03) (Figure 1a) . The 5-year PFS was 49% between 1983 and 1999 and 57% between 2000 and 2010 (P = 0.17) (Figure 1b) . The 5-year CI of relapse was 24% between 1983-1999 and 34% between 2000-2010 (P = 0.08) (Figure 1c ). NRM at 5 years was significantly higher during the 1983-1999 period compared with the 2000-2010 period (9% versus 27%, P = 0.0002) (Figure 1d ). We next determined whether the evolution of the allo-SCT source had a beneficial impact on the outcome of the SR versus the HR group. In the former group, the OS and the PFS did not improve over time (OS: 62%, range: 51-75 during the first period and 65%, range: 55-75 in the latest decade, P = 0.60; for PFS: 59%, range: 48-72% versus 58% (range, 49-69), respectively P = 1.00). Interestingly, in the HR group, the OS was significantly lower between 1983 and 1999 (37%, range: 24-56) compared with the latest period (62%, range: 49-78) (P = 0.01). The OS that was significantly higher in the SR compared with the HR group (P = 0.006) between 1983 and 1999, was comparable in the latest period (P = 0.61). We also observed a significantly lower 5-year PFS between 1983 and 1999 as compared with the 2000 and 2010 periods in the HR group (34%, range: 22-53; 55%, range: 42-71, respectively, P = 0.05). The 5-year NRM decreased significantly between the first and the second periods in both SR (25% versus 9%, P = 0.006) and HR groups (29% versus 10%, P = 0.01).
The CI of grade I-IV acute GvHD was not significantly different between the two periods (49% for the 1983-1999 versus 58% for the 2000-2010, P = 0.14). The same held true for the incidence of acute GvHD grade III-IV (23% versus 15%, P = 0.08). The CI of chronic limited or extensive GvHD was 18% in the 1983-1999 period and 19% in the 2000-2010 period (P = 0.94), and that of extensive chronic GvHD was similar (11%, P = 0.79) for the two periods. Considering only unrelated BM/peripheral blood stem cell, the cumulative incidence of acute GvHD was not different between the two periods (66.7% in the first period versus 70.4% in the second period, P = 0.82).
Causes of death
The causes of death are detailed in Table 2 . The CI of death related only to infections was 9% in the earlier period and 5% in the most recent period (P = 0.37). Similarly, the CI of relapse-related mortality was similar in both periods (19% for 1983-1999 versus 26% for 2000-2010, P = 0.26). Compared with the 1983-1999 period, the CI of death related to GvHD was significantly reduced after 2000 (13% versus 3%, P = 0.001).
DISCUSSION
In this large retrospective analysis, some notable trends were identified in the use of allo-SCT for children and adolescents in our center over the studied period. First, we observed an increased number of allo-SCT in the pediatric population. Such increase is probably multifactorial, namely the availability of new donor sources, in particular UCB SC, and the development of UCB banks; 36 the selection of better matched unrelated UCB transplants 37 and the use of unrelated donors based on an improved knowledge of this type of graft. 38 The median age of recipients was lower in the 2000-2010 period (8.2 years old) compared with the 1983-2009 period (11.4 years old), corresponding to broadened selection criteria related to a better understanding of the role of transplants in younger children and infants. Moreover, new conditioning regimens, such as RIC, have been recently developed for pediatric patients [39] [40] [41] and have enabled proposal of allo-SCT to patients with comorbidities, and also second allo-SCT.
Our data show a significant improvement of OS related to the reduction in NRM but with stable relapse rates. These results are in accordance with Mateos et al. 42 who found a survival gain (OS and event-free survival) due to TRM reduction in allo-SCT for pediatric ALL. Focusing on the risk status disease, 5-year OS and 5-year PFS were significantly improved in the HR group between 1983 and 1999 period and 2000 and 2010, but this was not observed in the SR group. It should be emphasized that determination of the risk status of disease has notably evolved over the years, and so have been the indications of allo-SCT. SR in the second period is much better defined than previously. The standard risk group in the second period is a selection of patients with poor criteria. Indeed, only AML with HR cytogenetic were transplanted in the second period and only ALL with poor early response to front line induction or relapse reinduction were transplanted. Indeed, the achievement of minimal residual disease, and not only hematological remission, is today a well-established criterion for transplant decisions in ALL patients. 43, 44 MRD at the end of induction and later in therapy has been shown in several cooperative group studies to be a strong, if not the strongest, predictor of outcome for patients with ALL. [45] [46] [47] This limitation has to be considered in this retrospective study.
In our study, the incidence of grade 3-4 GvHD was comparable between the two periods. However, the CI of deaths due to GvHD was significantly lower in the 2000-2010 period compared with 1983-1999 (3% versus 13%, P = 0.001). GvHD prophylaxis did not change substantially between the two periods. The main change has been the supportive care associated with GVH treatment: antifungal and pre-emptive antiviral therapy, earlier diagnosis of infections and thus earlier initiation of treatment. [48] [49] [50] Notably, in both groups, the improvement of NRM over time was statistically significant. Patients with GvHD are deeply immunocompromised, with a poor immunological reconstitution due to immunosuppressive treatments, and infections are the major cause of death. The improvement of OS without improvement of PFS may also be due to the development of second line treatment after allo-SCT such as inhibitors of tyrosine kinase for Ph+ALL or chronic myeloid leukemia, and also second allograft feasibility thanks to the development of the RIC regimen.
However, no improvement in the CI of deaths was observed, owing to relapse or progression, between the 1983-1999 and 2000-2010 periods. These data are in agreement with previous studies. 38, 42 Relapse remained the major cause of death post allo-SCT. Therefore, therapeutic advances are needed for both a better control of the pre-transplant disease and an improved post-transplant management. Recent mechanistic insights in leukemogenesis, concerning especially epigenetic modifications and aberrant activation of signaling pathways (break-point cluster region-Abelson (BCR-ABL), FMS-like tyrosine kinase 3, Janusassociated kinase), have led to the discovery of novel agents that specifically target the mechanisms of transformation. [51] [52] [53] In parallel, emerging approaches in cancer immunotherapy have led to novel therapies. A number of monoclonal antibodies have been recently developed, or are currently under investigation, for treatment of pediatric acute leukemia, including unconjugated antibodies (for example, epratuzumab), antibodies conjugated to cytotoxic agents (for example, gemtuzumab 54 ), antibodies conjugated to toxins such as Pseudomonas or Diptheria toxins (for example, moxetumomab pasudotox), and T-cell engaging bi-specific antibodies that redirect cytotoxic T lymphocytes to lyse target ALL cells (for example, blinatumomab). 55 Adoptive transfer of T cells engineered to express a chimeric antigen receptor has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory populations. 56 Incorporating these new therapeutic approaches to the overall management of allo-SCT will be one of the challenging issues in pediatric hematological malignancies for the next decade.
In conclusion, despite limitations related to its retrospective nature, this study provides data, which strongly suggest that major advances in supportive care practice and management of One choking and one unknown.
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